{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T01:06:44Z","timestamp":1789002404840,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":77,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01547-2","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T19:45:06Z","timestamp":1782416706000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0192-6975","authenticated-orcid":false,"given":"Shin Yeu","family":"Ong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jomel Meeko","family":"Manzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6360-3234","authenticated-orcid":false,"given":"Reid","family":"Merryman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsh","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Stuver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7892-2625","authenticated-orcid":false,"given":"Sanjal H.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7349-0176","authenticated-orcid":false,"given":"Ann","family":"LaCasce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayo","family":"Falade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey","family":"Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nivetha","family":"Ganesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1860-2424","authenticated-orcid":false,"given":"Urshila","family":"Durani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamer","family":"Othman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6098-1603","authenticated-orcid":false,"given":"Philippe","family":"Armand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1109-6955","authenticated-orcid":false,"given":"Matthew","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison J.","family":"Moskowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex F.","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"1547_CR1","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1093\/annonc\/mdf221","volume":"13","author":"A Josting","year":"2002","unstructured":"Josting A, Rudolph C, Reiser M, Mapara M, Sieber M, Kirchner HH, et al. Time-intensified dexamethasone\/cisplatin\/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin\u2019s disease. Ann Oncol. 2002;13:1628\u201335.","journal-title":"Ann Oncol"},{"key":"1547_CR2","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1093\/annonc\/mdm090","volume":"18","author":"NL Bartlett","year":"2007","unstructured":"Bartlett NL, Niedzwiecki D, Johnson JL, Friedberg JW, Johnson KB, van Besien K, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin\u2019s lymphoma: CALGB 59804. Ann Oncol. 2007;18:1071\u20139.","journal-title":"Ann Oncol"},{"key":"1547_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3324\/haematol.10661","volume":"92","author":"A Santoro","year":"2007","unstructured":"Santoro A, Magagnoli M, Spina M, Pinotti G, Siracusano L, Michieli M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin\u2019s lymphoma. Haematologica. 2007;92:35\u201341.","journal-title":"Haematologica"},{"key":"1547_CR4","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1182\/blood-2011-10-388058","volume":"119","author":"CH Moskowitz","year":"2012","unstructured":"Moskowitz CH, Matasar MJ, Zelenetz AD, Nimer SD, Gerecitano J, Hamlin P, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non\u2013cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood. 2012;119:1665\u201370.","journal-title":"Blood"},{"key":"1547_CR5","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1007\/s00277-014-2114-0","volume":"93","author":"J Labrador","year":"2014","unstructured":"Labrador J, Cabrero-Calvo M, P\u00e9rez-L\u00f3pez E, Mateis MV, Vazquez L, Caballero MD, et al. ESHAP as salvage therapy for relapsed or refractory Hodgkin\u2019s lymphoma. Ann Hematol. 2014;93:1745\u201353.","journal-title":"Ann Hematol"},{"key":"1547_CR6","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","volume":"132","author":"AS LaCasce","year":"2018","unstructured":"LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Maous J, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018;132:40\u20138.","journal-title":"Blood"},{"key":"1547_CR7","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1093\/annonc\/mdx791","volume":"29","author":"AF Herrera","year":"2018","unstructured":"Herrera AF, Palmer J, Martin P, Armenian S, Tsai N-C, Kennedy N, et al. Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Ann Oncol. 2018;29:724\u201330.","journal-title":"Ann Oncol"},{"key":"1547_CR8","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1470-2045(15)70013-6","volume":"16","author":"AJ Moskowitz","year":"2015","unstructured":"Moskowitz AJ, Sch\u00f6der H, Yahalom J, McCall SJ, Fox SY, Gerecitano J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin\u2019s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015;16:284\u201392.","journal-title":"Lancet Oncol"},{"key":"1547_CR9","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.21.01056","volume":"39","author":"AJ Moskowitz","year":"2021","unstructured":"Moskowitz AJ, Shah G, Sch\u00f6der H, Ganesan N, Drill E, Hancock H, et al. Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical hodgkin lymphoma. J Clin Oncol. 2021;39:3109\u201317.","journal-title":"J Clin Oncol"},{"key":"1547_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70126","volume":"9","author":"M Mei","year":"2025","unstructured":"Mei M, Palmer J, Lee HJ, et al. Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high-risk relapsed\/refractory Hodgkin lymphoma. Hemasphere. 2025;9:e70126.","journal-title":"Hemasphere"},{"key":"1547_CR11","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1182\/blood.2022015423","volume":"139","author":"MG Mei","year":"2022","unstructured":"Mei MG, Lee HJ, Palmer JM, Isufi I, Chen R, Tsai N-C, et al. Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE. Blood. 2022;139:3605\u201316.","journal-title":"Blood"},{"key":"1547_CR12","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.3324\/haematol.2022.282266","volume":"108","author":"K Ding","year":"2023","unstructured":"Ding K, Liu H, Ma J, Yang H, Cao L, Wang H, et al. Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial. Haematologica. 2023;108:2146\u201354.","journal-title":"Haematologica"},{"key":"1547_CR13","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1001\/jamaoncol.2022.7975","volume":"9","author":"LJ Bryan","year":"2023","unstructured":"Bryan LJ, Casulo C, Allen PB, Smith SE, Savas H, Dillehay GL, et al. Pembrolizumab added to ifosfamide, carboplatin, and etoposide chemotherapy for relapsed or refractory classic Hodgkin lymphoma: a multi-institutional phase 2 investigator-initiated nonrandomized clinical trial. JAMA Oncol. 2023;9:683\u201391.","journal-title":"JAMA Oncol"},{"key":"1547_CR14","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1056\/NEJMoa2206125","volume":"387","author":"SM Ansell","year":"2022","unstructured":"Ansell SM, Radford J, Connors JM, Dugosz-Danecka M, Km W-S, Gallamini A, et al. Overall survival with brentuximab vedotin in stage III or IV Hodgkin\u2019s lymphoma. N Engl J Med. 2022;387:310\u201320.","journal-title":"N Engl J Med"},{"key":"1547_CR15","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/ajh.26827","volume":"98","author":"SH Desai","year":"2023","unstructured":"Desai SH, Spinner MA, David K, et al. Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed\/refractory classic Hodgkin lymphoma. Am J Hematol. 2023;98:464\u201371.","journal-title":"Am J Hematol"},{"key":"1547_CR16","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1182\/bloodadvances.2020003556","volume":"5","author":"RW Merryman","year":"2021","unstructured":"Merryman RW, Redd RA, Nishihori T, et al. Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. Blood Adv. 2021;5:1648\u201359.","journal-title":"Blood Adv"},{"key":"1547_CR17","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1182\/blood.2025030151","volume":"147","author":"SH Desai","year":"2026","unstructured":"Desai SH, Moskowitz AJ, Merryman RW, Shah H, Pederson LD, Geyer SM. PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma. Blood. 2026;147:1125\u201334.","journal-title":"Blood"},{"key":"1547_CR18","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwarz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368.","journal-title":"J Clin Oncol"},{"key":"1547_CR19","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/bjh.15801","volume":"185","author":"A Romano","year":"2019","unstructured":"Romano A, Parrinello NL, Chiarenza A, Motta G, Tibullo D, Giallongo C, et al. Immune off-target effects of Brentuximab Vedotin in relapsed\/refractory Hodgkin Lymphoma. Br J Haematol. 2019;185:468\u201379.","journal-title":"Br J Haematol"},{"key":"1547_CR20","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/1535-7163.MCT-23-0118","volume":"23","author":"RA Heiser","year":"2024","unstructured":"Heiser RA, Cao AT, Zeng W, Ulrich M, Younan P, Anderson ME, et al. Brentuximab vedotin-driven microtubule disruption results in endoplasmic reticulum stress leading to immunogenic cell death and antitumor immunity. Mol Cancer Ther. 2024;23:68\u201383.","journal-title":"Mol Cancer Ther"},{"key":"1547_CR21","doi-asserted-by":"publisher","first-page":"3833","DOI":"10.1182\/bloodadvances.2025018683","volume":"10","author":"AS Falade","year":"2026","unstructured":"Falade AS, Redd R, Desai SH, Moskowitz AJ, Shah H, Geyer SM. Impact of novel therapies on the efficacy of post-transplantation brentuximab vedotin maintenance in Hodgkin lymphoma. Blood Adv. 2026;10:3833\u201344.","journal-title":"Blood Adv"},{"key":"1547_CR22","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1182\/blood-2021-148139","volume":"138","author":"C Bachier","year":"2021","unstructured":"Bachier C, Schade H, Zoghi B, Ramakrishnan A, Shah NN. A phase II single arm study of nivolumab as maintenance therapy after autologous stem cell transplantation in patients with Hodgkin lymphoma at risk of relapse or progression. Blood. 2021;138:2455","journal-title":"Blood"},{"key":"1547_CR23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood.2019000215","volume":"134","author":"P Armand","year":"2019","unstructured":"Armand P, Chen Y-B, Redd RA, Joyce RM, Bsat J, Jeter E, et al. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood. 2019;134:22\u20139.","journal-title":"Blood"},{"key":"1547_CR24","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41584-022-00841-0","volume":"18","author":"A Tison","year":"2022","unstructured":"Tison A, Garaud S, Chiche L, Cornec D, Kostine M. Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases. Nat Rev Rheumatol. 2022;18:641\u201356.","journal-title":"Nat Rev Rheumatol"},{"key":"1547_CR25","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO-25-00439","volume":"43","author":"J Ferdinandus","year":"2025","unstructured":"Ferdinandus J, Kaul H, Foss\u00e5 A, Huttmann A, Keil F, Ko Y-D, et al. Positron emission tomography-guided brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone in older patients with advanced-stage classic Hodgkin lymphoma: a prospective, multicenter, single-arm, phase II cohort of the German Hodgkin Study Group HD21 trial. J Clin Oncol. 2025;43:2974\u201385.","journal-title":"J Clin Oncol"},{"key":"1547_CR26","doi-asserted-by":"publisher","first-page":"322","DOI":"10.6004\/jnccn.2022.0021","volume":"20","author":"RT Hoppe","year":"2022","unstructured":"Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Armand P, Bello CM, et al. NCCN guidelines\u00ae insights: Hodgkin lymphoma, version 2.2022. J Natl Compr Canc Netw. 2022;20:322\u201334.","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01547-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01547-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01547-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:24:35Z","timestamp":1788999875000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01547-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1547"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01547-2","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"2 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AM reports research support from ADC Therapeutics, Beigene, Miragen, Seattle Genetics, Merck, Bristol-Myers Squibb, Incyte, and SecuraBio. She reports honoraria from Affimed, Imbrium Therapeutics L.P.\/Purdue, Janpix Ltd., Merck, Seattle Genetics, and Takeda. PA reports Consultancy: Merck, BMS\/Celgene, GenMab, Enterome, Genentech\/Roche, ATB Therapeutics, Regeneron; Research funding: Kite; Research funding (institutional): Merck, BMS\/Celgene, Adaptive, Genentech, IGM, Astra Zeneca, Pfizer. MM reports consultancy with Novartis, SeaGen, CTI, ADC Therapeutics, AstraZeneca, Synthekine; speakers\u2019 Bureau with SeaGen, Incyte; and research funding (institutional) from BMS, Incyte, Beigene, Genentech. AFH reports research funding from BMS, Merck, Genentech,Inc\/F. Hoffmann-La Roche Ltd, Gilead Sciences, SeaGen, AstraZeneca,and ADC Therapeutics, and consultancy for BMS, Merck, Genentech,Inc\/F. Hoffmann-La Roche Ltd, Kite Pharma\/Gilead, SeaGen,Karyopharm, Takeda, Tubulis, AstraZeneca, Genmab, ADC Ther-apeutics, and Regeneron. The remaining authors declare no competing financial interest","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The study was approved by the IRB of each participating institution. All IRBs waived the requirement for informed consent.","order":2,"name":"Ethics","label":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"152"}}